European Patent Office Upholds Angiotech's Patent For Drug-Coated Stents

Law360 (January 24, 2005, 12:00 AM EST) -- The European Patent Office has upheld the validity of Canadian medical device maker Angiotech Pharmaceuticals’ patent on specially coated medical stents, the company said Monday.

The EPO maintained the validity of Angiotech's patent with various claims, including claims to stents coated with paclitaxel and a polymeric carrier.

“This decision reaffirms Angiotech's continued patent protection in Europe,” the company said in a statement.

The patent is one of many in Angiotech's portfolio, including the Boston Scientific Taxus stent program. The stents, coated with paclitaxel and a polymeric...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.